$KMB

Analyst recommendations: Kimberly-Clark, Palantir, Snap, Crowdstrike

Analysts updated recommendations for multiple companies. Kimberly-Clark (KMB) was downgraded to underperform with a higher price target. Palantir (PLTR) was upgraded to buy. Snap (SNAP) was upgraded to buy with a slightly lower target. Accenture (ACN) and others saw price target increases.

Original reporting
Published Aug 24, 2026, 9:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 10:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$KMB
Bearish
medium confidence
Mentioned
$KMB · $PLTR · $SNAP · $CRWD · $ACN · $ABNB
Relevance
5/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$KMBBearishMed
01

Why it matters

Aggregated rating changes provide modest signals; individual stock moves likely muted unless reinforced by other news.

02

Market read

Collective upgrades/downgrades may cause slight sector rotation but no major market mover.

03

What to watch

Potential earnings releases later in the day could dominate price action over analyst revisions.

Relevance 5/10Novelty 5/10Timing: morning release

Background

Morning analyst recommendation roundup covering multiple US-listed companies.

Company-level read

Ticker impact

$KMBBearishMedium confidence
Context

Baptista Research downgrades Kimberly-Clark to underperform and raises price target to $113.90.

Expected impact

Modest decline of 1‑2% in near term.

Evidence & confidence

Downgrade signals weaker outlook; price target increase is modest and may not offset.

$PLTRBullishMedium confidence
Context

William O'Neil & Co upgrades Palantir to buy from coverage suspended.

Expected impact

Potential 2‑3% rise if market reacts.

Evidence & confidence

New coverage and buy rating often lift sentiment.

$SNAPNeutralLow confidence
Context

Baptista Research upgrades Snap to buy from outperform and lowers price target to $6.80.

Expected impact

Flat to slight uptick, 0‑1% range.

Evidence & confidence

Target cut suggests concerns despite rating upgrade.

$CRWDBullishMedium confidence
Context

Jefferies maintains buy on Crowdstrike and raises price target to $230.

Expected impact

Possible 1‑2% gain.

Evidence & confidence

Higher target aligns with buy rating, could attract buyers.

$ACNNeutralLow confidence
Context

Citi maintains neutral on Accenture and raises price target to $190.

Expected impact

Little to no movement.

Evidence & confidence

No rating change, only target lift.

$ABNBBullishMedium confidence
Context

Bernstein maintains outperform on Airbnb and raises price target to $217.

Expected impact

Modest upside, ~1% potential.

Evidence & confidence

Higher target reinforces existing bullish view.

$ADIBullishMedium confidence
Context

Baird maintains outperform on Analog Devices and raises price target to $675.

Expected impact

Potential 2‑3% rise.

Evidence & confidence

Large target increase signals confidence.

$LHBullishLow confidence
Context

HSBC maintains hold on Labcorp and raises price target to $330.

Expected impact

Potential 1% rise.

Evidence & confidence

Hold rating limits upside.

Market effects

Analyst rating shifts may influence broader tech and industrial sectors.

US market sentiment may adjust modestly in early trade.

Limited to US-listed equities; no direct global macro effect.

Counterpoint

Some upgrades are offset by target cuts, suggesting caution despite rating changes.

Key entities

  • Baptista Research

    Provides rating updates for Kimberly-Clark and Snap.

  • William O'Neil & Co

    Upgraded Palantir to buy.

Related articles

$MRNAHigh

Moderna-Merck personalized mRNA melanoma vaccine cuts relapse risk in late-stage trial

Moderna and Merck reported late-stage trial results showing their personalized mRNA melanoma vaccine, intismeran, reduced relapse risk by 42% when combined with Keytruda. The trial involved 1,137 patients, with 82% of vaccine recipients showing no recurrence after two years, compared to 70% for the placebo group. The companies plan to present the findings at a medical conference and continue long-term studies.

$CRWDHigh

CrowdStrike Stock Jumps As Nvidia AI Pact Ignites Bull Case

CrowdStrike Holdings Inc. (CRWD) stock rose 8.43% on October 23, 2026, driven by strong cybersecurity demand and a new AI collaboration with Nvidia. The company's revenue grew over 25% annually to $4.81B, with a gross margin of 75.3%. Analysts raised price targets, citing AI security growth and the Falcon Flex model's success. CRWD's stock traded between $220 and $257.57 recently, showing strong momentum.

$CRWDHigh

CrowdStrike Stock Jumps As Nvidia AI Security Deal Ignites Bull Thesis

CrowdStrike Holdings Inc. (CRWD) stock rose 8.43% on October 23, 2026, following a partnership with Nvidia for AI security. The collaboration involves CrowdStrike's Falcon Guardian AI running on Nvidia's OpenShell and Sentry. Analysts upgraded price targets, citing AI-driven demand and the company's Flex subscription model. CrowdStrike reported $4.81B in annual revenue, with strong growth and cash flow.

$MRNAMedAI 8/10

Moderna stock extends losses as investors digest melanoma vaccine trial data

Moderna (MRNA) shares fell 1% on Friday, following a 17% drop the prior day, as investors reacted to leaked data from a late-stage melanoma vaccine trial. The data, set for official release on Saturday, initially underwhelmed investors. Analysts' price targets vary, with Goldman Sachs at $137, Morgan Stanley at $95, and Citi at $80. The stock has rallied this year on hopes for its cancer treatment pipeline.